CHRU Jean Minjoz
CHRU Jean Minjoz
Besançon, France4 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib | ovarian carcinosarcoma | Recruiting | Phase 2 / Phase 3 | 2026-09-09 | NCT03651206 | |
| Study Evaluating the Safety Feasibility and Efficacy of ODI-2001 Vaccine, a Personnalized Immunotherapy in Patients With Metastatic or Locally Advanced Colon Cancer or Pancreatic Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, endocrine system disorder, intestinal disorder, malignant endocrine neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm, rectal disorder | Not yet recruiting | Phase 1 | 2026-05-14 | NCT07587827 | |
| Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasm Metastasis, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, Urogenital Neoplasms, endometrium neoplasm, female reproductive system disorder, female reproductive system neoplasm, neoplasm, uterine disorder | Active, not recruiting | Phase 3 | 2025-12-04 | NCT05201547 | |
| Immunomonitoring of Breast Cancer Patients During Systemic Treatment | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Not applicable | 2023-10-17 | NCT04925856 |